Muna Bhanji - Jul 6, 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/ James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jul 6, 2023
Transactions value $
-$73,373
Form type
4
Date filed
7/10/2023, 05:21 PM
Previous filing
Jun 21, 2023
Next filing
Jul 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$73.4K -1.87K -12.97% $39.30 12.5K Jul 6, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported sale of 1,867 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 6, 2023 at each separate price.